Larimar Therapeutics

LRMRPhase 2

Larimar Therapeutics is dedicated to addressing rare diseases with significant unmet medical needs through its proprietary intracellular protein replacement platform. Its lead candidate, CTI-1601, is a recombinant fusion protein designed to deliver human frataxin to the mitochondria of patients with Friedreich's ataxia, a debilitating and life-shortening neurodegenerative disorder. The company is advancing CTI-1601 through clinical development while exploring its platform's potential for other rare diseases. Larimar's strategy centers on demonstrating proof-of-concept in Friedreich's ataxia to validate its technology and create value for patients and shareholders.

Market Cap

$465.1M

Employees

20-50

Focus

Biotech

LRMR · Stock Price

USD 4.49+0.55 (+13.96%)

Historical price data

AI Company Overview

Technology Platform

An intracellular protein replacement platform designed to deliver functional proteins to specific compartments inside cells (e.g., mitochondria) via recombinant fusion proteins for subcutaneous administration.

Pipeline Snapshot

5 drugs in pipeline

Drug	Indication	Stage
CTI-1601	Friedreich Ataxia	Phase 2
CTI-1601	Friedreich Ataxia	Phase 2
Nomlabofusp + Placebo	Friedreich Ataxia	Phase 1
CTI-1601 + Placebo	Friedreich Ataxia	Phase 1
CTI-1601 + Placebo	Friedreich Ataxia	Phase 1

Funding History

Total raised: $155M

PIPE$100MChiesi Global Rare DiseasesFeb 15, 2021

Series B$45MChiesi Global Rare DiseasesJun 15, 2020

Series A$10MChiesi Global Rare DiseasesJan 15, 2019

Opportunities

Success with CTI-1601 in Friedreich's ataxia would validate Larimar's platform and unlock its application to other rare diseases caused by intracellular protein deficiencies, representing a significantly larger market.

The lack of any approved root-cause therapy for FA creates a clear commercial pathway for a first-in-class treatment.

Risk Factors

The primary risk is clinical failure of CTI-1601, as the company's value is concentrated in this single asset.

Demonstrating that increased frataxin in accessible tissues translates to meaningful clinical benefit in the heart and nervous system is unproven.

Regulatory hurdles, safety issues, and future competition from gene therapies also pose significant threats.

Competitive Landscape

Larimar's main competitor is Biogen's Skyclarys®, an approved Nrf2 activator, but CTI-1601's direct protein replacement mechanism is distinct. It also faces emerging competition from gene therapy (Voyager/Neurocrine) and gene activation (Design Therapeutics) programs. Larimar differentiates through its chronic, subcutaneous, direct protein delivery approach.

Publications

Patents

Pipeline